Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

aTyr Pharma Inc (LIFE)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow aTyr Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
1.640 +0.040    +2.50%
22/04 - Closed. Currency in USD ( Disclaimer )
After Hours
1.690
+0.050
+3.049%
19:30:29 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 293,399
  • Bid/Ask: 1.610 / 1.700
  • Day's Range: 1.575 - 1.685
aTyr Pharma 1.640 +0.040 +2.50%

aTyr Pharma Inc Company Profile

 
Get an in-depth profile of aTyr Pharma Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

58

Equity Type

ORD

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

Contact Information

Address 10240 Sorrento Valley Road Suite 300
San Diego, 92121
United States
Phone 858 731 8389
Fax 858 731 8394

Top Executives

Name Age Since Title
Osamu Nureki - 2009 Member of Scientific Advisory Board
Wing Hung Wong - - Member of Scientific Advisory Board
John K. Clarke 70 2005 Independent Director
Nancy Ip - - Member of Scientific Advisory Board
Timothy J. Rink 78 2011 Member of Therapeutic Advisory Board
Paul Negulescu - 2011 Member of Therapeutic Advisory Board
R. Alan B. Ezekowitz 70 - Member of Therapeutic Advisory Board
Sanjay S. Shukla 52 2016 President, CEO & Director
Svetlana Lucas 52 2019 Independent Director
Sara L. Zaknoen 65 2021 Independent Director
Paul R. Schimmel 83 2005 Independent Director
Benjamin F. Cravatt 53 - Member of Scientific Advisory Board
Douglas Edward Williams 66 2011 Member of Therapeutic Advisory Board
Bruce A. Beutler - 2009 Member of Scientific Advisory Board
Leonard Patrick Gage 82 2011 Member of Therapeutic Advisory Board
Keith James - 2011 Member of Therapeutic Advisory Board
Arthur M. Mercurio - 2020 Scientific Advisor
Timothy P. Coughlin 57 2017 Independent Chairman of the Board
Jane A. Gross 67 2019 Independent Director
Thomas O. Daniel 70 2011 Member of Therapeutic Advisory Board
Wendell D. Wierenga 76 2011 Member of Therapeutic Advisory Board
Floyd E. Bloom 87 2009 Member of Scientific Advisory Board
Susan L. Ackerman - - Member of Scientific Advisory Board
Richard A. Heyman 67 2011 Member of Therapeutic Advisory Board
Judith Varner - 2021 Scientific Advisor
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

LIFE Comments

Write your thoughts about aTyr Pharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Brett Govindasamy
Brett Govindasamy Sep 16, 2021 10:13AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Well....i take my comment back!!
Faris Banjar
Faris Banjar Sep 16, 2021 9:55AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Stock of today !!!!!!!!!!!
Brett Govindasamy
Brett Govindasamy Sep 16, 2021 9:06AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Something not right about this.
Faris Banjar
Faris Banjar Sep 14, 2021 11:03AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Stock of the day !! 👌🏻👌🏻
Czar Freeman
Czar Sep 14, 2021 9:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
it's revenue is in the 5hiter, can be a reddit rally
Atis Atis
Atis Atis Sep 14, 2021 6:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
i think to invest , will it go up today ?
julie ram
julie ram Sep 13, 2021 11:54AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Tonix Pharmaceuticals Announces Results of Pre-IND Meeting with FDA for TNX-1800 as a Potential Vaccine to Prevent COVID-19By
Hugh Jazz
Hugh Jazz Mar 16, 2021 3:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
anyone here?
Omar Joiee
Omar Joiee Feb 11, 2021 3:11PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
price going for 10$
Daniel Bulut
Daniel Bulut Feb 09, 2021 10:32AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
why noone here... :d
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email